ATE467640T1 - Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen - Google Patents

Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen

Info

Publication number
ATE467640T1
ATE467640T1 AT07863316T AT07863316T ATE467640T1 AT E467640 T1 ATE467640 T1 AT E467640T1 AT 07863316 T AT07863316 T AT 07863316T AT 07863316 T AT07863316 T AT 07863316T AT E467640 T1 ATE467640 T1 AT E467640T1
Authority
AT
Austria
Prior art keywords
17rcx4
soluble
inflammation
present
receptor
Prior art date
Application number
AT07863316T
Other languages
German (de)
English (en)
Inventor
Rolf E Kuestner
Zeren Gao
Steven D Levin
Mark W Rixon
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE467640T1 publication Critical patent/ATE467640T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT07863316T 2006-02-10 2007-02-09 Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen ATE467640T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77217706P 2006-02-10 2006-02-10
US78107806P 2006-03-10 2006-03-10
PCT/US2007/061909 WO2008039553A1 (en) 2006-02-10 2007-02-09 Soluble il-17rcx4 and methods of using in inflammation

Publications (1)

Publication Number Publication Date
ATE467640T1 true ATE467640T1 (de) 2010-05-15

Family

ID=38895865

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07863316T ATE467640T1 (de) 2006-02-10 2007-02-09 Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen

Country Status (10)

Country Link
US (2) US7622116B2 (OSRAM)
EP (1) EP1987058B1 (OSRAM)
JP (1) JP2009526084A (OSRAM)
AT (1) ATE467640T1 (OSRAM)
AU (1) AU2007300393B2 (OSRAM)
CA (1) CA2638819A1 (OSRAM)
DE (1) DE602007006429D1 (OSRAM)
ES (1) ES2347840T3 (OSRAM)
IL (1) IL192950A0 (OSRAM)
WO (1) WO2008039553A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001871A (zh) * 2004-06-10 2007-07-18 津莫吉尼蒂克斯公司 可溶性ZcytoR14、抗ZcytoR14抗体和结合伴侣以及在炎症中的使用方法
CA2679588A1 (en) 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
AU2008266745B2 (en) * 2007-06-20 2014-04-17 Merck Sharp & Dohme Corp. Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease
GB2464183A (en) * 2008-09-19 2010-04-14 Singulex Inc Sandwich assay
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP2810652A3 (en) * 2009-03-05 2015-03-11 AbbVie Inc. IL-17 binding proteins
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
JP2011032170A (ja) * 2009-07-29 2011-02-17 Morinaga Milk Ind Co Ltd ヒト細胞ｉｌ−１７産生抑制剤
US20130011413A1 (en) * 2010-02-03 2013-01-10 The University Of Tokyo Method and Pharmaceutical Composition for Treatment of Intestinal Disease
WO2011140484A1 (en) 2010-05-06 2011-11-10 Singulex, Inc Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis
RU2535033C2 (ru) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
EP2663647A4 (en) 2011-01-14 2015-08-19 Redwood Bioscience Inc POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
US11492396B2 (en) 2015-10-27 2022-11-08 UCB Biopharma SRL Methods of treatment using anti-IL-17A/F antibodies
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
WO2020147829A1 (zh) * 2019-01-17 2020-07-23 北京百奥赛图基因生物技术有限公司 人源化转基因动物
BR112022002962A2 (pt) 2019-08-16 2022-07-05 Applied Molecular Transport Inc Composições, formulações e produção e purificação de interleucina
CN112250764B (zh) * 2020-10-22 2022-07-29 深圳市康瑞克生物科技有限责任公司 一种抗白细胞介素17a的单克隆抗体、其编码基因及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684032A (en) 1994-12-13 1997-11-04 Smithkline Beecham Corporation Compounds
MX9707021A (es) 1995-03-23 1997-11-29 Immunex Corp Receptor de il-7.
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
WO1999058660A1 (en) 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
US6569645B2 (en) 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20020177188A1 (en) 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
WO1998049307A1 (en) 1997-05-01 1998-11-05 Zymogenetics, Inc. Mammalian cytokine-like receptor
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
DE69841140D1 (de) 1997-09-17 2009-10-22 Human Genome Sciences Inc Interleukin-17 rezeptor-ähnliches protein
DK1190056T3 (da) 1999-07-07 2007-07-30 Zymogenetics Inc Human cytokin receptor
US20030199041A1 (en) 1999-07-07 2003-10-23 Presnell Scott R. Interleukin-17 receptor homologue
ATE519847T1 (de) 1999-12-23 2011-08-15 Genentech Inc Il-17-homologe polypeptide und ihre therapeutische verwendung
US20030092881A1 (en) 2000-05-24 2003-05-15 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
WO2001090357A1 (en) 2000-05-24 2001-11-29 Genesis Research & Development Corporation Limited Compositions isolated from skin cells and methods for their use
WO2002058717A2 (en) * 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
US20040171109A1 (en) 2000-11-10 2004-09-02 Dominik Haudenschild IL-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
US20040097447A1 (en) 2002-11-16 2004-05-20 Isis Pharmaceuticals Inc. Modulation of interleukin 22 receptor expression
CN101001871A (zh) 2004-06-10 2007-07-18 津莫吉尼蒂克斯公司 可溶性ZcytoR14、抗ZcytoR14抗体和结合伴侣以及在炎症中的使用方法
CA2596509A1 (en) * 2005-02-14 2006-08-24 Wyeth Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
WO2007038703A2 (en) * 2005-09-28 2007-04-05 Zymogenetics, Inc Il-17a and il-17f antagonists and methods of using the same
US20070249533A1 (en) * 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same

Also Published As

Publication number Publication date
WO2008039553A8 (en) 2009-07-16
EP1987058B1 (en) 2010-05-12
CA2638819A1 (en) 2008-04-03
DE602007006429D1 (de) 2010-06-24
ES2347840T3 (es) 2010-11-04
AU2007300393A1 (en) 2008-04-03
WO2008039553A1 (en) 2008-04-03
AU2007300393B2 (en) 2012-05-31
EP1987058A1 (en) 2008-11-05
US20100113748A1 (en) 2010-05-06
US7622116B2 (en) 2009-11-24
JP2009526084A (ja) 2009-07-16
US20070196371A1 (en) 2007-08-23
IL192950A0 (en) 2009-02-11
US8093355B2 (en) 2012-01-10

Similar Documents

Publication Publication Date Title
ATE467640T1 (de) Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen
DE602006016965D1 (de) Il-17a- und il-17f-antagonisten und verwendungsverfahren
MXPA06014465A (es) Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion.
WO2007106769A3 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
ATE474856T1 (de) Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
ATE475673T1 (de) Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
WO2008133684A8 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
WO2009082624A3 (en) Antagonists of il-17a, il-17f, and il-23 and methods of using the same
FR16C1004I1 (fr) Methode de traitement du cancer resistant au gefitinib
TW200507849A (en) Methods for treating interleukin-6 related diseases
ATE523196T1 (de) Mitotische kinesinhemmer und verfahren zu ihrer verwendung
MX2009010273A (es) Proteinas de fusion il-17ra/rc solubles y metodos relacionados.
WO2005052001A3 (en) Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
ATE524546T1 (de) Verwendung von anti-tnf oder anti-il1-rnai zur unterdrückung der wirkung entzündungsfördernder cytokine zur lokalen schmerzbehandlung
WO2008049070A3 (en) Il-17c antagonists and methods of using the same
WO2011079308A3 (en) Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
DE602007008276D1 (de) Neues verfahren für die biologische bekämpfung des ausbreitens von legionella pneumophila, und neues desinfektionsmittel, das amöben-protozoen der gattung willaertia enthält
DE602006008583D1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
MX2007004597A (es) Zcytor21 soluble, anticuerpos anti-zcytor21 y moleculas de enlace y metodos de uso en inflamacion.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1987058

Country of ref document: EP